Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth M Swisher

Showing results (51-60 of 194) with videos related to

Pageof 20
Sort By:
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|February 10, 2012
PAX2 loss by immunohistochemistry occurs early and often in endometrial hyperplasiaKimberly H Allison, Kristen Upson, Susan D Reed, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2011
Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomasBarbara Norquist, Kaitlyn A Wurz, Christopher C Pennil, et al.
Gynecologic Oncology Reports|August 31, 2019
Patterns and duration of primary and recurrent treatment in ovarian cancer patients with germline <i>BRCA</i> mutationsSoledad Jorge, Elizabeth M Swisher, Barbara M Norquist, et al.
Ebiomedicine|February 21, 2023
Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in ARIEL2 & STUDY 10Olivier Colomban, Elizabeth M Swisher, Rebecca Kristeleit, et al.
American Journal of Obstetrics and Gynecology|June 26, 2012
Biomarkers of progestin therapy resistance and endometrial hyperplasia progressionKristen Upson, Kimberly H Allison, Susan D Reed, et al.
Gynecologic Oncology|December 30, 2019
Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-makingSoledad Jorge, Andrew S McFaddin, Kemi M Doll, et al.
Neoplasia (New York, N.Y.)|December 21, 2010
Identification of a preneoplastic gene expression profile in tubal epithelium of BRCA1 mutation carriersJoshua Z Press, Kaitlyn Wurz, Barbara M Norquist, et al.
Cancer Research|September 3, 2010
BRCA1-associated epigenetic regulation of p73 mediates an effector pathway for chemosensitivity in ovarian carcinomaNageatte Ibrahim, Lei He, Chee-Onn Leong, et al.
Familial Cancer|February 26, 2020
Perceptions of risk and reward in BRCA1 and BRCA2 mutation carriers choosing salpingectomy for ovarian cancer preventionTalayeh S Ghezelayagh, Lauren E Stewart, Barbara M Norquist, et al.
JCO Precision Oncology|October 14, 2022
State of the Biomarker Science in Ovarian Cancer: A National Cancer Institute Clinical Trials Planning Meeting ReportJosee-Lyne Ethier, Katherine C Fuh, Rebecca Arend, et al.
Pageof 20

Showing results (51-60 of 194) with videos related to

Sort By:
Pageof 20
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|February 10, 2012
PAX2 loss by immunohistochemistry occurs early and often in endometrial hyperplasiaKimberly H Allison, Kristen Upson, Susan D Reed, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2011
Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomasBarbara Norquist, Kaitlyn A Wurz, Christopher C Pennil, et al.
Gynecologic Oncology Reports|August 31, 2019
Patterns and duration of primary and recurrent treatment in ovarian cancer patients with germline <i>BRCA</i> mutationsSoledad Jorge, Elizabeth M Swisher, Barbara M Norquist, et al.
Ebiomedicine|February 21, 2023
Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in ARIEL2 & STUDY 10Olivier Colomban, Elizabeth M Swisher, Rebecca Kristeleit, et al.
American Journal of Obstetrics and Gynecology|June 26, 2012
Biomarkers of progestin therapy resistance and endometrial hyperplasia progressionKristen Upson, Kimberly H Allison, Susan D Reed, et al.
Gynecologic Oncology|December 30, 2019
Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-makingSoledad Jorge, Andrew S McFaddin, Kemi M Doll, et al.
Neoplasia (New York, N.Y.)|December 21, 2010
Identification of a preneoplastic gene expression profile in tubal epithelium of BRCA1 mutation carriersJoshua Z Press, Kaitlyn Wurz, Barbara M Norquist, et al.
Cancer Research|September 3, 2010
BRCA1-associated epigenetic regulation of p73 mediates an effector pathway for chemosensitivity in ovarian carcinomaNageatte Ibrahim, Lei He, Chee-Onn Leong, et al.
Familial Cancer|February 26, 2020
Perceptions of risk and reward in BRCA1 and BRCA2 mutation carriers choosing salpingectomy for ovarian cancer preventionTalayeh S Ghezelayagh, Lauren E Stewart, Barbara M Norquist, et al.
JCO Precision Oncology|October 14, 2022
State of the Biomarker Science in Ovarian Cancer: A National Cancer Institute Clinical Trials Planning Meeting ReportJosee-Lyne Ethier, Katherine C Fuh, Rebecca Arend, et al.
Pageof 20